Option chain shows key data for Ipsen's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Ipsen.

Ipsen (OTC:IPSEF) Stock, Option Chain

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Equities

News

Health Care

Media

General

GNFT

IPSEF

IPSEY

The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug&#39;s ability to reduce alkaline phosphatase levels, marks a significant advancement in therapies available for PBC.

FDA Fast-Tracks Ipsen And Genfit&#39;s New Liver Disease Treatment, Iqirvo

Biotech

Trading Ideas

EXEL

RHHBF

RHHBY

RHHVF

Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&amp;nbs

Third Time Lucky: Exelixis&#39; Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients

Penny Stocks

Termination

Small Cap

Analyst Ratings

Movers

CBAY

DRRX

ICPT

On Friday, FDA&#39;s Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc&#39;s ICPT Ocaliva 25 mg, also known as Obeticholic acid (OCA), don&#39;t outweigh the risks in nonalcoholic steatohepatitis (NASH) 

What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept&#39;s &#39;OCA In NASH May Never Occur

Ipsen SA

Ipsen

Comments

Ipsen

Ipsen (IPSEF) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell